parecoxib has been researched along with valdecoxib in 46 studies
| Studies (parecoxib) | Trials (parecoxib) | Recent Studies (post-2010) (parecoxib) | Studies (valdecoxib) | Trials (valdecoxib) | Recent Studies (post-2010) (valdecoxib) |
|---|---|---|---|---|---|
| 436 | 186 | 229 | 375 | 71 | 86 |
| Protein | Taxonomy | parecoxib (IC50) | valdecoxib (IC50) |
|---|---|---|---|
| Cytochrome c oxidase subunit 2 | Homo sapiens (human) | 1.1 | |
| Carbonic anhydrase 1 | Homo sapiens (human) | 0.1915 | |
| Carbonic anhydrase 2 | Homo sapiens (human) | 1.0086 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 2.927 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 2.927 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.0631 | |
| Carbonic anhydrase 9 | Homo sapiens (human) | 0.027 | |
| Carbonic anhydrase 4 | Bos taurus (cattle) | 0.2658 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 32 (69.57) | 29.6817 |
| 2010's | 13 (28.26) | 24.3611 |
| 2020's | 1 (2.17) | 2.80 |
| Authors | Studies |
|---|---|
| Bechmann, N; Kniess, T; Köckerling, M; Pietzsch, J; Roscales, S; Weiss, DH | 1 |
| Jain, KK | 1 |
| Crosby-Sessoms, SL; Hubbard, RC; Karim, A; Kuss, ME; Laurent, A; Qian, J; Slater, ME | 1 |
| Hardy, KJ; McMurray, RW | 1 |
| Frölich, JC; Stichtenoth, DO | 1 |
| Alston, RP; Duke, PC; Feneck, RO; Hsu, PH; Hubbard, RC; Mangano, DT; Nussmeier, NA; Ott, E; Saidman, LJ; Snabes, MC | 1 |
| Daniels, S; Desjardins, PJ; Hubbard, RC; Mehlisch, DR | 1 |
| Cryer, B | 1 |
| Burian, M; Geisslinger, G | 1 |
| Cheung, RY; Cippolle, M; Fort, JG; Gan, TJ; Joshi, GP; Minkowitz, H; Schuller, R; Viscusi, ER | 1 |
| Møiniche, S; Rømsing, J | 1 |
| Chen, C; Cheung, RY; Dodge, W; Fort, JG; Gan, TJ; Joshi, GP; Viscusi, E | 1 |
| Chen, C; Cleeland, CS; Hanna, DB; Jensen, MP; Mendoza, T | 1 |
| Benoit, V; de Leval, X; Dogné, JM; Frederich, M; Julémont, F; Pirotte, B | 1 |
| Chen, C; Cheung, RY; Gan, TJ; Hanna, DB; Joshi, GP; Zhao, SZ | 1 |
| FitzGerald, GA; Furberg, CD; Psaty, BM | 1 |
| Boyce, SW; Brown, MT; Hoeft, A; Langford, RM; Nussmeier, NA; Parlow, JL; Verburg, KM; Whelton, AA | 1 |
| Furberg, CD; Psaty, BM | 1 |
| Drazen, JM | 1 |
| Cheung, R; Jensen, MP; Martin, SA | 1 |
| Aziz, Q; Delaney, C; Hobson, AR; Thompson, DG; Willert, RP; Woolf, CJ | 1 |
| Meechan, J | 1 |
| Aldington, S; Beasley, R; Shirtcliffe, P; Weatherall, M | 1 |
| Boye, ME; Brown, MT; Joshi, GP; Langford, RM; Nussmeier, NA; Singla, NK; Verburg, KM; Whelton, AA | 1 |
| Bucher, M; Hobbhahn, J; Kees, FK; Lunz, D; Messmann, B; Rath, S; Schlitt, HJ; Zelenka, M | 1 |
| Bittner, R; Junginger, W; Kraft, B; Leroy, S; Schweizer, M | 1 |
| Al-Sukhun, J; Koivusalo, A; Lindqvist, C; Törnwall, J | 1 |
| Deray, G; Montalescot, G; Sibilia, J | 1 |
| Engelman, E; Salengros, JC | 1 |
| Bello, A; Cheung, R; Johnston, A; Langford, RM; Mehta, V | 1 |
| Benson, SE; Charteris, DG; Khan, I; Langford, RM; Newsom, R; Ratclliffe, S; Schlottmann, PG; Van Raders, P | 1 |
| Camu, F; Cheung, R; Joshi, GP; Pan, S; Schug, SA | 1 |
| Chen, C; Chen, WH; Gan, TJ; Joshi, GP; Langford, RM; Mattera, MS; Revicki, DA; Zlateva, G | 1 |
| Bankstahl, M; Löscher, W; Polascheck, N | 1 |
| Elliott, WJ | 1 |
| Fuskevåg, OM; Reikerås, O; Shegarfi, H; Utvåg, SE | 1 |
| Becker, A; Höllt, V; Schröder, H | 1 |
| Del Carlo, S; Giorgi, M; Macchia, M; Manera, C; Saba, A; Saccomanni, G | 1 |
| Del Carlo, S; Giorgi, M; Lavy, E; Manera, C; Saccomanni, G | 1 |
| Ilett, KF; Muchatuta, NA; O'Halloran, SJ; Paech, MJ; Salman, S | 1 |
| Davies, K; Hullett, B; Ilett, KF; O'Halloran, SJ; Peirce, D; Salman, S | 1 |
| Darabi, A; Eberstål, S; Fritzell, S; Sandén, E; Siesjö, P; Visse, E | 1 |
| Briganti, A; Giorgi, M; Kim, TW; Re, G; Vercelli, C | 1 |
| Fang, M; He, Z; Li, P; Liu, M; Liu, X; Sun, B; Sun, J; Sun, M; Sun, Y; Wang, Y; Yu, Q; Zhang, P; Zhu, M | 1 |
| Cheng, C; Jia, Y; Jin, X; Liu, Y; Wang, G; Yao, L; Zhang, J; Zhou, F | 1 |
| Li, SB; Li, SL; Li, ZH; Qiu, XJ; Zhu, CY; Zhu, YL | 1 |
11 review(s) available for parecoxib and valdecoxib
| Article | Year |
|---|---|
Evaluation of intravenous parecoxib for the relief of acute post-surgical pain.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Isoxazoles; Membrane Proteins; Pain, Postoperative; Prodrugs; Prostaglandin-Endoperoxide Synthases; Sulfonamides | 2000 |
Cox-2 inhibitors: today and tomorrow.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Enzyme Inhibitors; Etoricoxib; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Research; Sulfonamides; Sulfones | 2002 |
The second generation of COX-2 inhibitors: what advantages do the newest offer?
Topics: Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Drug Interactions; Etoricoxib; Humans; Isoenzymes; Isoxazoles; Membrane Proteins; Organic Chemicals; Prostaglandin-Endoperoxide Synthases; Pyridines; Sulfonamides; Sulfones | 2003 |
The role of cyclooxygenase selective inhibitors in the gastrointestinal tract.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Digestive System; Etoricoxib; Humans; Isoxazoles; Pyridines; Sulfonamides; Sulfones; Ulcer | 2003 |
[Clinical pharmacology of the selective COX-2 inhibitors].
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Clinical Trials, Phase III as Topic; Cyclooxygenase Inhibitors; Diclofenac; Humans; Isoxazoles; Lactones; Naproxen; Osteoarthritis; Pain; Pain, Postoperative; Placebos; Pyrazoles; Sulfonamides; Sulfones | 2003 |
A systematic review of COX-2 inhibitors compared with traditional NSAIDs, or different COX-2 inhibitors for post-operative pain.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Humans; Isoxazoles; Lactones; Pain Measurement; Pain, Postoperative; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Sulfones; Treatment Outcome | 2004 |
First and second generations of COX-2 selective inhibitors.
Topics: Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etoricoxib; Gastrointestinal Diseases; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Sulfonamides; Sulfones | 2004 |
Increased risk of cardiovascular events with parecoxib/valdecoxib: a systematic review and meta-analysis.
Topics: Cardiac Surgical Procedures; Cardiovascular Diseases; Cerebrovascular Disorders; Cyclooxygenase Inhibitors; Humans; Isoxazoles; Myocardial Infarction; Odds Ratio; Outcome and Process Assessment, Health Care; Pain, Postoperative; Risk Factors; Sulfonamides; Survival Analysis | 2005 |
[What do we know about the cardiovascular toxicity of the NSAIDs?].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Follow-Up Studies; Humans; Isoxazoles; Lactones; Meta-Analysis as Topic; Middle Aged; Naproxen; Pyrazoles; Randomized Controlled Trials as Topic; Risk Factors; Sulfonamides; Sulfones; Thrombosis; Time Factors | 2006 |
Cardiovascular safety of the cyclooxygenase-2 selective inhibitors parecoxib and valdecoxib in the postoperative setting: an analysis of integrated data.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Female; Humans; Incidence; Isoxazoles; Male; Middle Aged; Pain, Postoperative; Postoperative Care; Risk Assessment; Risk Factors; Sulfonamides; Thromboembolism; Young Adult | 2009 |
Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Hypertension; Isoxazoles; Lactones; Pyrazoles; Pyridines; Risk; Risk Factors; Sulfonamides; Sulfones | 2010 |
19 trial(s) available for parecoxib and valdecoxib
| Article | Year |
|---|---|
A pharmacokinetic study of intramuscular (i.m.) parecoxib sodium in normal subjects.
Topics: Adolescent; Adult; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Cyclooxygenase Inhibitors; Double-Blind Method; Humans; Injections, Intramuscular; Isoxazoles; Male; Middle Aged; Sulfonamides | 2001 |
Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery.
Topics: Administration, Oral; Adult; Aged; Analgesia; Analgesia, Patient-Controlled; Coronary Artery Bypass; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Injections, Intravenous; Isoenzymes; Isoxazoles; Male; Membrane Proteins; Middle Aged; Morphine; Pain Measurement; Prospective Studies; Prostaglandin-Endoperoxide Synthases; Safety; Sulfonamides | 2003 |
Single doses of parecoxib sodium intravenously are as effective as ketorolac in reducing pain after oral surgery.
Topics: Adult; Analgesics; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Double-Blind Method; Female; Humans; Injections, Intravenous; Isoenzymes; Isoxazoles; Ketorolac; Male; Membrane Proteins; Molar, Third; Pain Measurement; Pain, Postoperative; Prodrugs; Prostaglandin-Endoperoxide Synthases; Safety; Sulfonamides; Survival Analysis; Time Factors; Tooth Extraction | 2003 |
Effective treatment of laparoscopic cholecystectomy pain with intravenous followed by oral COX-2 specific inhibitor.
Topics: Administration, Oral; Adult; Cholecystectomy, Laparoscopic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Double-Blind Method; Female; Humans; Injections, Intravenous; Isoenzymes; Isoxazoles; Male; Membrane Proteins; Middle Aged; Pain Measurement; Pain, Postoperative; Prostaglandin-Endoperoxide Synthases; Sulfonamides | 2004 |
Preoperative parenteral parecoxib and follow-up oral valdecoxib reduce length of stay and improve quality of patient recovery after laparoscopic cholecystectomy surgery.
Topics: Administration, Oral; Analysis of Variance; Cholecystectomy, Laparoscopic; Double-Blind Method; Female; Humans; Isoxazoles; Length of Stay; Male; Middle Aged; Multivariate Analysis; Postoperative Care; Preoperative Care; Sulfonamides | 2004 |
The analgesic effects that underlie patient satisfaction with treatment.
Topics: Adult; Analgesics; Cholecystectomy, Laparoscopic; Double-Blind Method; Drug Administration Routes; Drug Administration Schedule; Female; Humans; Isoxazoles; Male; Middle Aged; Morphine; Outcome Assessment, Health Care; Pain Measurement; Pain, Postoperative; Patient Satisfaction; Postoperative Care; Preoperative Care; Prospective Studies; Retrospective Studies; Sex Factors; Sulfonamides; Time Factors | 2004 |
Presurgical intravenous parecoxib sodium and follow-up oral valdecoxib for pain management after laparoscopic cholecystectomy surgery reduces opioid requirements and opioid-related adverse effects.
Topics: Administration, Oral; Adolescent; Adult; Aged; Analgesics, Opioid; Cholecystectomy, Laparoscopic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Double-Blind Method; Female; Humans; Hydrocodone; Injections, Intravenous; Isoenzymes; Isoxazoles; Male; Membrane Proteins; Middle Aged; Pain Measurement; Pain, Postoperative; Prostaglandin-Endoperoxide Synthases; Sulfonamides | 2004 |
Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.
Topics: Administration, Oral; Adult; Aged; Cardiovascular Diseases; Coronary Artery Bypass; Cyclooxygenase Inhibitors; Double-Blind Method; Female; Humans; Infusions, Intravenous; Isoxazoles; Male; Middle Aged; Pain, Postoperative; Sulfonamides | 2005 |
The meaning of pain relief in a clinical trial.
Topics: Administration, Oral; Adult; Analgesia; Analgesics; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Isoxazoles; Male; Middle Aged; Pain Measurement; Pain, Postoperative; Patient Satisfaction; Sulfonamides; Treatment Outcome | 2005 |
Constitutive cyclo-oxygenase-2 does not contribute to the development of human visceral pain hypersensitivity.
Topics: Adult; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Drug Administration Schedule; Electric Stimulation; Esophagus; Female; Humans; Hydrochloric Acid; Isoxazoles; Male; Middle Aged; Pain Threshold; Sulfonamides; Viscera | 2006 |
COX-2 inhibitors and pain after oral surgery - pertinent papers 2002-2003.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Ibuprofen; Injections, Intravenous; Isoxazoles; Lactones; Pain, Postoperative; Preanesthetic Medication; Prodrugs; Pyrazoles; Sulfonamides; Sulfones; Tooth Extraction | 2006 |
Safety and efficacy of the cyclooxygenase-2 inhibitors parecoxib and valdecoxib after noncardiac surgery.
Topics: Adult; Aged; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Female; Humans; Isoxazoles; Male; Middle Aged; Morphine; Pain, Postoperative; Sulfonamides | 2006 |
Prostaglandin I2 release following mesenteric traction during abdominal surgery is mediated by cyclooxygenase-1.
Topics: 6-Ketoprostaglandin F1 alpha; Abdomen; Blood Pressure; Cyclooxygenase 1; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Epoprostenol; Female; Flushing; Heart Rate; Humans; Hypotension; Intraoperative Complications; Isoxazoles; Laparoscopy; Male; Middle Aged; Oxygen; Prospective Studies; Sulfonamides; Surgical Procedures, Operative; Tachycardia; Time Factors; Treatment Outcome | 2006 |
[Analgesia in colon surgery. Can the use of NSAIDs reduce the opioid consumption following conventional and laparoscopic interventions?].
Topics: Acetaminophen; Administration, Oral; Adult; Aged; Analgesia, Patient-Controlled; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Colonic Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Isoxazoles; Laparoscopy; Male; Middle Aged; Pain Measurement; Pain, Postoperative; Pirinitramide; Prospective Studies; Rectal Diseases; Sulfonamides | 2006 |
Intravenous parecoxib rapidly leads to COX-2 inhibitory concentration of valdecoxib in the central nervous system.
Topics: Aged; Central Nervous System; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Female; Humans; Inhibitory Concentration 50; Injections, Intravenous; Isoxazoles; Male; Middle Aged; Sulfonamides; Time Factors | 2008 |
A randomized comparison of parecoxib/valdecoxib and placebo for the prevention of cystoid macular edema after scleral buckling surgery.
Topics: Administration, Oral; Adolescent; Adult; Aged; Contrast Sensitivity; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Female; Fluorescein Angiography; Humans; Incidence; Isoxazoles; Macular Edema; Male; Middle Aged; Prospective Studies; Retinal Detachment; Scleral Buckling; Subretinal Fluid; Sulfonamides; Tomography, Optical Coherence; Visual Acuity; Young Adult | 2009 |
Reduction in opioid-related adverse events and improvement in function with parecoxib followed by valdecoxib treatment after non-cardiac surgery: a randomized, double-blind, placebo-controlled, parallel-group trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Attitude of Health Personnel; Cyclooxygenase Inhibitors; Double-Blind Method; Drug Evaluation; Drug Therapy, Combination; Elective Surgical Procedures; Female; Humans; Isoxazoles; Male; Middle Aged; Pain, Postoperative; Patient Satisfaction; Placebos; Psychometrics; Sulfonamides | 2009 |
Pharmacokinetics of intravenous and intramuscular parecoxib in healthy Beagles.
Topics: Acute Pain; Analgesia; Animals; Area Under Curve; Chromatography, High Pressure Liquid; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Dogs; Half-Life; Injections, Intramuscular; Injections, Intravenous; Isoxazoles; Male; Prodrugs; Sulfonamides | 2012 |
The pharmacokinetics and in vitro/ex vivo cyclooxygenase selectivity of parecoxib and its active metabolite valdecoxib in cats.
Topics: Animals; Area Under Curve; Cats; Cyclooxygenase Inhibitors; Isoxazoles; Male; Sulfonamides | 2014 |
16 other study(ies) available for parecoxib and valdecoxib
| Article | Year |
|---|---|
Novel valdecoxib derivatives by ruthenium(ii)-promoted 1,3-dipolar cycloaddition of nitrile oxides with alkynes - synthesis and COX-2 inhibition activity.
Topics: | 2018 |
Parecoxib, valdecoxib, and cardiovascular risk.
Topics: Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoxazoles; Membrane Proteins; Meta-Analysis as Topic; Prodrugs; Product Surveillance, Postmarketing; Prostaglandin-Endoperoxide Synthases; Randomized Controlled Trials as Topic; Risk Assessment; Sulfonamides | 2005 |
COX-2 inhibitors--lessons in drug safety.
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Approval; Gastrointestinal Hemorrhage; Humans; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Publishing; Pyrazoles; Randomized Controlled Trials as Topic; Research Design; Sulfonamides; Sulfones; United States; United States Food and Drug Administration | 2005 |
COX-2 inhibitors--a lesson in unexpected problems.
Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Approval; Gastrointestinal Hemorrhage; Humans; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones | 2005 |
COX-2 inhibitors and early failure of free vascular flaps.
Topics: Cyclooxygenase 2 Inhibitors; Humans; Isoxazoles; Pain, Postoperative; Sulfonamides; Surgical Flaps; Treatment Failure | 2006 |
Safety of parecoxib and valdecoxib after noncardiac surgery: lack of demonstration.
Topics: Cyclooxygenase 2 Inhibitors; Humans; Isoxazoles; Pain, Postoperative; Safety; Sulfonamides | 2007 |
The COX-2 inhibitor parecoxib is neuroprotective but not antiepileptogenic in the pilocarpine model of temporal lobe epilepsy.
Topics: Analysis of Variance; Animals; Cell Count; Cell Death; Cerebral Cortex; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Electrodes, Implanted; Electroencephalography; Enzyme-Linked Immunosorbent Assay; Epilepsy, Temporal Lobe; Female; Isoxazoles; Motor Activity; Neurons; Neuroprotective Agents; Pilocarpine; Random Allocation; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Statistics, Nonparametric; Sulfonamides; Video Recording | 2010 |
Short-term treatment with COX-2 inhibitors does not impair fracture healing.
Topics: Animals; Bone Density; Cyclooxygenase 2 Inhibitors; Diclofenac; Fracture Healing; Isoxazoles; Male; Rats; Rats, Wistar; Sulfonamides | 2010 |
Parecoxib and its metabolite valdecoxib directly interact with cannabinoid binding sites in CB1-expressing HEK 293 cells and rat brain tissue.
Topics: Amino Acids; Animals; Binding, Competitive; Brain Chemistry; Cyclic AMP; Cyclohexanols; Cyclooxygenase 2 Inhibitors; gamma-Aminobutyric Acid; Glutamic Acid; Guanosine 5'-O-(3-Thiotriphosphate); HEK293 Cells; Humans; Isoxazoles; Male; Radioligand Assay; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Sulfonamides; Transfection | 2011 |
Simultaneous detection and quantification of parecoxib and valdecoxib in canine plasma by HPLC with spectrofluorimetric detection: development and validation of a new methodology.
Topics: Animals; Chromatography, High Pressure Liquid; Cyclooxygenase 2 Inhibitors; Dogs; Isoxazoles; Sensitivity and Specificity; Spectrometry, Fluorescence; Sulfonamides | 2011 |
Transfer of parecoxib and its primary active metabolite valdecoxib via transitional breastmilk following intravenous parecoxib use after cesarean delivery: a comparison of naive pooled data analysis and nonlinear mixed-effects modeling.
Topics: Adult; Biological Transport; Cesarean Section; Cyclooxygenase 2 Inhibitors; Female; Humans; Infant, Newborn; Injections, Intravenous; Isoxazoles; Male; Milk, Human; Models, Biological; Nonlinear Dynamics; Sulfonamides | 2012 |
Development of a population pharmacokinetic model for parecoxib and its active metabolite valdecoxib after parenteral parecoxib administration in children.
Topics: Adult; Age Factors; Algorithms; Biotransformation; Child; Child, Preschool; Computer Simulation; Cyclooxygenase 2 Inhibitors; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Infant; Infusions, Parenteral; Isoxazoles; Male; Models, Statistical; Nonlinear Dynamics; Population; Prospective Studies; Reproducibility of Results; Sulfonamides | 2012 |
Intratumoral COX-2 inhibition enhances GM-CSF immunotherapy against established mouse GL261 brain tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Drug Synergism; Female; Flow Cytometry; Glioma; Granulocyte-Macrophage Colony-Stimulating Factor; Immunoenzyme Techniques; Immunotherapy; Intramolecular Oxidoreductases; Isoxazoles; Mice; Mice, Inbred C57BL; Prostaglandin-E Synthases; Sulfonamides; Tumor Cells, Cultured | 2014 |
Simultaneous determination of parecoxib sodium and its active metabolite valdecoxib in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study after intravenous and intramuscular administration.
Topics: Administration, Intravenous; Animals; Chromatography, High Pressure Liquid; Injections, Intramuscular; Isoxazoles; Linear Models; Male; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity; Sulfonamides; Tandem Mass Spectrometry | 2016 |
Simultaneous determination of parecoxib and its main metabolites valdecoxib and hydroxylated valdecoxib in mouse plasma with a sensitive LC-MS/MS method to elucidate the decreased drug metabolism of tumor bearing mice.
Topics: Animals; Cell Line, Tumor; Chromatography, High Pressure Liquid; Cyclooxygenase 2 Inhibitors; Cytochrome P-450 Enzyme System; Drug Monitoring; Female; Humans; Isoxazoles; Mice; Mice, Inbred BALB C; Neoplasms; Oxazoles; Prodrugs; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Sulfonamides; Tandem Mass Spectrometry; Xenograft Model Antitumor Assays | 2018 |
Simultaneous Determination of Parecoxib and Its Metabolite Valdecoxib Concentrations in Beagle Plasma by UPLC-MS/MS and Application for Pharmacokinetics Study.
Topics: Animals; Chromatography, High Pressure Liquid; Dogs; Injections, Intramuscular; Isoxazoles; Molecular Structure; Sulfonamides; Tandem Mass Spectrometry | 2020 |